651 reports of this reaction
2.2% of all UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE reports
#7 most reported adverse reaction
PNEUMONIA is the #7 most commonly reported adverse reaction for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 651 FDA adverse event reports linking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to PNEUMONIA. This represents approximately 2.2% of all 30,147 adverse event reports for this drug.
Patients taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is a less commonly reported adverse event for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to pneumonia, the following adverse reactions have been reported for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 651 FDA reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 2.2% of all adverse event reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience pneumonia while taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.